Medivation (NASDAQ:MDVN) : 15 Wall Street analysts covering Medivation (NASDAQ:MDVN) believe that the average level the stock could reach for the short term is $61. The maximum price target given is $76 and the minimum target for short term is around $40, hence the standard deviation is calculated at $11.05.
Shares of Medivation, Inc. appreciated by 1.75% during the last five trading days but lost 1.37% on a 4-week basis. Medivation, Inc. is up 30.55% in the last 3-month period. Year-to-Date the stock performance stands at 24.74%. Also, Equity Analysts at the Citigroup upgrades the rating on Medivation (NASDAQ:MDVN). The brokerage firm has issued a Buy rating on the shares. The shares were previously rated Neutral. The Analysts at the ratings agency raises the price target from $37 per share to $73 per share. The rating by the firm was issued on May 6, 2016.
Medivation (NASDAQ:MDVN) : Zacks Investment Research ranks Medivation (NASDAQ:MDVN) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.62, which indicates as a Buy.
Medivation (NASDAQ:MDVN): The stock opened at $60.62 on Thursday but the bulls could not build on the opening and the stock topped out at $61.21 for the day. The stock traded down to $60.02 during the day, due to lack of any buying support eventually closed down at $60.30 with a loss of -1.07% for the day. The stock had closed at $60.95 on the previous day. The total traded volume was 2,998,898 shares.
In an insider trading activity, Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., unloaded 2,578 shares at an average price of $60.42 on June 6, 2016. The total amount of the transaction was worth $155,763, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.